ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "morbidity and mortality and rheumatoid arthritis (RA)"

  • Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting

    Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus

    Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
  • Abstract Number: 2810 • 2014 ACR/ARHP Annual Meeting

    Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts

    Sam Norton1, Elena Nikiphorou2, Lewis Carpenter3, David Walsh4,5, Patrick Kiely6, Josh Dixey7 and Adam Young2,8, 1Institute of Psychiatry, King's College London, London, United Kingdom, 2School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, 4Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, 5Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, 6Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, 7Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, 8Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom

    Background/Purpose Rheumatoid arthritis (RA) is associated with a 20 to 30% increased risk of mortality from all-causes compared to the general population. The aim of…
  • Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting

    DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality

    Jie Zhang1, Fenglong Xie2, Lang Chen3, Huifeng Yun4, Paul M. Muntner5, Emily Levitan5, Monica Safford6, Kenneth G. Saag7, Jasvinder A. Singh6 and Jeffrey R. Curtis6, 1Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 5Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6University of Alabama at Birmingham, Birmingham, AL, 7Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…
  • Abstract Number: 1770 • 2013 ACR/ARHP Annual Meeting

    All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System

    Jessica Widdifield1,2, J. Michael Paterson1, Sasha Bernatsky3, Bindee Kuriya4, J. Carter Thorne5, Simon Hollands1 and Claire Bombardier6, 1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3McGill University, Montreal, QC, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between…
  • Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting

    Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study

    Diane Lacaille1, J. Antonio Avina-Zubieta2,3, Eric C. Sayre2, Michal Abrahamowicz4 and John Esdaile1,5, 1Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, 2Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, 5Medicine, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
  • Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting

    Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008

    Anne M. Kerola1, Tuomo Nieminen2, Lauri J. Virta3, Hannu Kautiainen4, Kari Puolakka5, Tuomas Kerola6, Timo Pohjolainen7 and Markku J. Kauppi6, 1Medical School, University of Helsinki, Helsinki, Finland, 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, 3Research Department, the Social Insurance Institution, Turku, Finland, 4Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 5Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 6Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 7ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland

    Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
  • Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting

    Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study

    Diane Lacaille1, Michal Abrahamowicz2, Eric C. Sayre3 and John Esdaile4, 1Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, 2Clinical Epidemiology, McGill University, Montreal, QC, Canada, 3Arthritis Research Centre of Canada, Vancouver, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
  • Abstract Number: 1245 • 2012 ACR/ARHP Annual Meeting

    Age-Specific Association Between Disease-Related Measures and Incident Cardiovascular Events and All-Cause Mortality in Early Rheumatoid Arthritis

    Sofia Ajeganova1, Maria LE Andersson2, Johan Frostegård3 and Ingiäld Hafström1, 1Karolinska Institutet, Unit of Rheumatology, Department of Medicine Huddinge, Stockholm, Sweden, 2R&D Center, Spenshult Hospital, Oskarström, Sweden, 3Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden

    Background/Purpose: Increased risk of cardiovascular disease (CVD) and premature mortality in rheumatoid arthritis (RA) has been established, but the impact of inflammatory and disease related…
  • Abstract Number: 822 • 2012 ACR/ARHP Annual Meeting

    Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis

    Shreyasee Amin1, Sherine E. Gabriel2, Sara J. Achenbach3, Elizabeth J. Atkinson3 and L. Joseph Melton III4, 1Rheumatology and Health Sciences Research, Mayo Clinic, Rochester, MN, 2Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Hlth Sciences, Mayo Clinic, Rochester, MN

    Background/Purpose: Women and men with RA are at an increased risk for fracture [fx] as well as greater overall mortality. It is recognized that in…
  • Abstract Number: 767 • 2012 ACR/ARHP Annual Meeting

    Patients with Early Inflammatory Arthritis Who Fulfil the 2010 American College Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Have Increased Mortality Compared to Those Who Do Not: Results From the Norfolk Arthritis Register

    Jh Humphreys1, Suzanne Verstappen2, Mark Lunt3, Jackie Chipping4, Kimme Hyrich5, Tarnya Marshall6 and Deborah Symmons7, 1Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, 5Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 6Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 7Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom

    Background/Purpose: Mortality is increased in rheumatoid arthritis (RA) in comparison with the general population.  The majority of studies have used the 1987 ACR criteria to…
  • Abstract Number: 357 • 2012 ACR/ARHP Annual Meeting

    Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?

    Dietmar MJ Krause1, Bernadette Gabriel2, Gertraud Herborn3 and Rolf Rau4, 1Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, 2Private Practice, Gladbeck, Germany, 3Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany, 4Evangelisches Fachkrankenhaus, Ratingen, Germany

    Background/Purpose: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA). MTX shows effects on disease activity, radiologic progression and mortality. These…
  • Abstract Number: 87 • 2012 ACR/ARHP Annual Meeting

    Prediction of Mortality in Rheumatoid Arthritis Using a Serum Cytokine Profile

    Agustin Escalante1, Roy W. Haas1, Daniel F. Battafarano2 and Inmaculada Del Rincon3, 1Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, 3Rheumatology, University of Texas Health Science Center, San Antonio, TX

    Background/Purpose: Cytokines are important in the pathogenesis of RA. Their concentration in the serum rises immediately prior to RA onset, and may be associated with…
  • Abstract Number: 70 • 2012 ACR/ARHP Annual Meeting

    The Impact of Systemic Autoimmune Rheumatic Disease On One-Year Mortality in Congestive Heart Failure Patients: A Population-Level Analysis

    Stephanie O. Keeling1, Asvina Bissonauth1, Becky Leung2 and Padmaja Kaul2, 1Medicine, University of Alberta, Edmonton, AB, Canada, 2Cardiology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Little is known about the prevalence of systemic autoimmune rheumatic diseases (SARDs) in patients with congestive heart failure (CHF) and its contribution to long-term…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology